Zinplava™ (bezlotoxumab)

Zinplava (bezlotoxumab) is covered only as a single 10 mg/kg IV infusion (over 60 minutes) to reduce recurrence of CDI in patients ≥1 year old who are currently receiving antibacterial therapy for CDI and are at high risk for recurrence; repeat dosing and prior bezlotoxumab recipients are excluded. Key requirements: documented current CDI with concurrent antibacterial treatment, age ≥1 year, documented high risk for recurrence, no prior bezlotoxumab, and approval limited to one 10 mg/kg dose.

"Reduce recurrence of Clostridioides difficile infection (CDI) in adults and pediatric patients 1 year of age and older who are receiving antibacterial drug treatment for CDI and are at high risk fo..."

Sign up to see full coverage criteria, indications, and limitations.